Login to Your Account



Onyx Rises on Positive Phase IIb Multiple Myeloma Data

By Donna Young


Tuesday, July 27, 2010
Onyx Pharmaceuticals Inc.'s investors were fired up Monday over top-line Phase IIb data that showed patients with relapsed-refractory multiple myeloma receiving carfilzomib as a single agent had an overall response rate of 24 percent, with a median duration of response of 7.4 months and no new or unexpected toxicities. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription